These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21383499)

  • 1. A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy.
    Narayanan P; Lapteva N; Seethammagari M; Levitt JM; Slawin KM; Spencer DM
    J Clin Invest; 2011 Apr; 121(4):1524-34. PubMed ID: 21383499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant.
    Kemnade JO; Seethammagari M; Narayanan P; Levitt JM; McCormick AA; Spencer DM
    Mol Ther; 2012 Jul; 20(7):1462-71. PubMed ID: 22434138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells.
    Schmitt S; Tahk S; Lohner A; Hänel G; Maiser A; Hauke M; Patel L; Rothe M; Josenhans C; Leonhardt H; Griffioen M; Deiser K; Fenn NC; Hopfner KP; Subklewe M
    Front Immunol; 2020; 11():602802. PubMed ID: 33281829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endotoxin-induced maturation of MyD88-deficient dendritic cells.
    Kaisho T; Takeuchi O; Kawai T; Hoshino K; Akira S
    J Immunol; 2001 May; 166(9):5688-94. PubMed ID: 11313410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.
    Wilson NS; Yang B; Morelli AB; Koernig S; Yang A; Loeser S; Airey D; Provan L; Hass P; Braley H; Couto S; Drane D; Boyle J; Belz GT; Ashkenazi A; Maraskovsky E
    Immunol Cell Biol; 2012 May; 90(5):540-52. PubMed ID: 21894173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation.
    Lapteva N; Seethammagari MR; Hanks BA; Jiang J; Levitt JM; Slawin KM; Spencer DM
    Cancer Res; 2007 Nov; 67(21):10528-37. PubMed ID: 17974997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
    Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
    Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.
    Hangalapura BN; Oosterhoff D; de Groot J; Boon L; Tüting T; van den Eertwegh AJ; Gerritsen WR; van Beusechem VW; Pereboev A; Curiel DT; Scheper RJ; de Gruijl TD
    Cancer Res; 2011 Sep; 71(17):5827-37. PubMed ID: 21747119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
    Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
    Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist.
    Jung ID; Jeong SK; Lee CM; Noh KT; Heo DR; Shin YK; Yun CH; Koh WJ; Akira S; Whang J; Kim HJ; Park WS; Shin SJ; Park YM
    Cancer Res; 2011 Apr; 71(8):2858-70. PubMed ID: 21368092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency.
    Kim JH; Kang TH; Noh KH; Bae HC; Ahn YH; Lee YH; Choi EY; Chun KH; Lee SJ; Kim TW
    Clin Exp Immunol; 2011 Aug; 165(2):180-9. PubMed ID: 21592111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncoupling of induced protein processing from maturation in dendritic cells exposed to a highly antigenic preparation from a helminth parasite.
    Marshall FA; Pearce EJ
    J Immunol; 2008 Dec; 181(11):7562-70. PubMed ID: 19017945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo.
    Hanks BA; Jiang J; Singh RA; Song W; Barry M; Huls MH; Slawin KM; Spencer DM
    Nat Med; 2005 Feb; 11(2):130-7. PubMed ID: 15665830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
    Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
    Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.
    Ali OA; Verbeke C; Johnson C; Sands RW; Lewin SA; White D; Doherty E; Dranoff G; Mooney DJ
    Cancer Res; 2014 Mar; 74(6):1670-81. PubMed ID: 24480625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
    Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
    BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect recruitment of a CD40 signaling pathway in dendritic cells by B7-DC cross-linking antibody modulates T cell functions.
    Radhakrishnan S; Cabrera R; Bruns KM; Van Keulen VP; Hansen MJ; Felts SJ; Pease LR
    PLoS One; 2009; 4(4):e5373. PubMed ID: 19399172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced protective immunity derived from dendritic cells with phagocytosis of CD40 ligand transgene-engineered apoptotic tumor cells via increased dendritic cell maturation.
    Parameswaran S; Khalil M; Ahmed KA; Sharma RK; Xiang J
    Tumori; 2015; 101(6):637-43. PubMed ID: 25983089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity.
    Collinson-Pautz MR; Slawin KM; Levitt JM; Spencer DM
    PLoS One; 2016; 11(10):e0164547. PubMed ID: 27741278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.